All In Biotech

Drug Trial Radar · NCT01764087

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 2012

Primary completion

Dec 2015

Study completion May 2016

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the maximum tolerated dose (MTD) of KX2-391 in Combination with paclitaxel in Phase I, and to evaluate the efficacy of KX2-391 in combination with paclitaxel in patients who are diagnosed as gastric and breast cancer, respectively in Phase II.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific
  • Gastric Cancer
  • Breast Cancer

Interventions

  • KX2-391 and PaclitaxelDrug

    A treatment cycle in phase I will consist of 28 days, according to the following schedule: KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle. The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated A treatment cycle in phase II will consist of 28 days, according to the following schedule: KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicities (DLTs) in Phase I PortionTime frame: From start of the treatment to end of cycle 1, which are 4 weeks
  2. Tumor Overall Response Rates (ORRs) in Phase II PortionTime frame: In every 2 cycles up to end of the treatment, an expected average of 16 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.